Genprex Inc
Company Profile
Business description
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company’s product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
Contact
3300 Bee Cave Road
Suite 650-227
AustinTX78746
USAT: +1 877 774-4679
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
Market pricing in further upside in overvalued ASX bank
stocks
Chart of the Week: Lithium is rebounding on rising demand
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,238.70 | 21.50 | 0.23% |
| CAC 40 | 8,428.70 | 67.24 | 0.80% |
| DAX 40 | 25,304.15 | 305.75 | 1.22% |
| Dow JONES (US) | 49,815.03 | 281.84 | 0.57% |
| FTSE 100 | 10,702.82 | 146.65 | 1.39% |
| HKSE | 26,705.94 | 138.82 | 0.52% |
| NASDAQ | 22,871.61 | 293.23 | 1.30% |
| Nikkei 225 | 57,143.84 | 577.35 | 1.02% |
| NZX 50 Index | 13,247.02 | 215.40 | 1.65% |
| S&P 500 | 6,901.50 | 58.28 | 0.85% |
| S&P/ASX 200 | 9,007.00 | 12.80 | 0.14% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |